<code id='AB867A2B44'></code><style id='AB867A2B44'></style>
    • <acronym id='AB867A2B44'></acronym>
      <center id='AB867A2B44'><center id='AB867A2B44'><tfoot id='AB867A2B44'></tfoot></center><abbr id='AB867A2B44'><dir id='AB867A2B44'><tfoot id='AB867A2B44'></tfoot><noframes id='AB867A2B44'>

    • <optgroup id='AB867A2B44'><strike id='AB867A2B44'><sup id='AB867A2B44'></sup></strike><code id='AB867A2B44'></code></optgroup>
        1. <b id='AB867A2B44'><label id='AB867A2B44'><select id='AB867A2B44'><dt id='AB867A2B44'><span id='AB867A2B44'></span></dt></select></label></b><u id='AB867A2B44'></u>
          <i id='AB867A2B44'><strike id='AB867A2B44'><tt id='AB867A2B44'><pre id='AB867A2B44'></pre></tt></strike></i>

          Home / explore / hotspot

          hotspot


          hotspot

          author:focus    Page View:8
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In